Blood Pressure Dynamics After Pubertal Suppression with Gonadotropin-Releasing Hormone Analogs Followed by Testosterone Treatment in Transgender Male Adolescents: A Pilot Study

Perl, Liat; Segev-Becker, Anat; Israeli, Galit; Elkon-Tamir, Erella; Oren, Asaf

doi:10.1089/lgbt.2020.0026

Cited by 14 publications

(39 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 In addition to body composition, metabolic effects as insulin sensitivity during CSHT, and changes in blood pressure during testosterone therapy were examined. [31][32][33] Of these studies, three originated from Amsterdam. 29,32,33 The Amsterdam studies included observations during GnRHa therapy, 28 1 year after starting CSHT, 32 as well as after a group median >5 years with CSHT in a cohort of 22-year-old adolescents.…”

Section: Body Composition and Metabolic Markersmentioning

confidence: 99%

“…[31][32][33] Of these studies, three originated from Amsterdam. 29,32,33 The Amsterdam studies included observations during GnRHa therapy, 28 1 year after starting CSHT, 32 as well as after a group median >5 years with CSHT in a cohort of 22-year-old adolescents. 31,33 The studies from Amsterdam were generally larger than the other studies.…”

Section: Body Composition and Metabolic Markersmentioning

confidence: 99%

“…CSHT changed body composition towards the affirmed sex. 31,32 Obesity (defined as BMI >30 at age 22 years) was more prevalent in the transgender population 33 (Table 4).…”

Section: Body Composition and Metabolic Markersmentioning

confidence: 99%

See 2 more Smart Citations

A systematic review of hormone treatment for children with gender dysphoria and recommendations for research

et al. 2023

View full text Add to dashboard Cite

AimThe aim of this systematic review was to assess the effects on psychosocial and mental health, cognition, body composition, and metabolic markers of hormone treatment in children with gender dysphoria.MethodsSystematic review essentially follows PRISMA. We searched PubMed, EMBASE and thirteen other databases until 9 November 2021 for English‐language studies of hormone therapy in children with gender dysphoria. Of 9934 potential studies identified with abstracts reviewed, 195 were assessed in full text, and 24 were relevant.ResultsIn 21 studies, adolescents were given gonadotropin‐releasing hormone analogues (GnRHa) treatment. In three studies, cross‐sex hormone treatment (CSHT) was given without previous GnRHa treatment. No randomised controlled trials were identified. The few longitudinal observational studies were hampered by small numbers and high attrition rates. Hence, the long‐term effects of hormone therapy on psychosocial health could not be evaluated. Concerning bone health, GnRHa treatment delays bone maturation and bone mineral density gain, which, however, was found to partially recover during CSHT when studied at age 22 years.ConclusionEvidence to assess the effects of hormone treatment on the above fields in children with gender dysphoria is insufficient. To improve future research, we present the GENDHOR checklist, a checklist for studies in gender dysphoria.

show abstract

Section: Body Composition and Metabolic Markersmentioning

confidence: 99%

Section: Body Composition and Metabolic Markersmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review of hormone treatment for children with gender dysphoria and recommendations for research

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Body weight management was at the center of attention, as obesity prevalence was 9.9% in trans girls and 6.6% in boys, compared to 2.2% and 3.0% in cis girls and boys [104]. No significant changes in blood pressure were seen in 28 trans adolescents treated with oral estrogen for 1 year or more [66], and this was confirmed in a retrospective study with 19 trans girls treated with GnRHa, of whom 15 continued with estrogen treatment [105].…”

Section: Resultsmentioning

confidence: 97%

Gender‐affirming hormone therapy: An updated literature review with an eye on the future

D'hoore

T’Sjoen

2022

J Intern Med

View full text Add to dashboard Cite

show abstract

“…Additionally, two cases of arterial hypertension following treatment with triptorelin, which resolved after discontinuation of GnRHa, were reported in 2020 and 2019 [24,25]. A recent study of blood pressure changes following induction of GnRHa therapy in 15 transgender male patients [26 ] found a significant but not hypertensive rise of diastolic blood pressure.…”

Section: Safety/adverse Events Associated With Gonadotropin-releasing...mentioning

confidence: 99%

Use of gonadotropin-releasing hormone analogs in children

Allen

Krishna

Lee

2021

Current Opinion in Pediatrics

View full text Add to dashboard Cite

Purpose of review In this review, we outline the usage and formulations of gonadotropin-releasing hormone analogs (GnRHas) in central precocious puberty (CPP), short stature, and gender diverse individuals, as well as adverse effects, long-term outcomes, and monitoring of therapy. There is a particular focus on citing references published within the last 24 months. Recent findings Long-acting formulations of GnRHa now include Federal Drug Administration approval for subcutaneous injections. Significant adverse events continue to be rarely reported; extremely rare events include arterial hypertension and pseudotumor cerebri. There continue to be no significant long-term consequences including the impact upon body mass index and bone mineral density, which appear to be transient. GnRHas have been used in differences of sexual development (DSD) and increasingly in the treatment of adolescent transgender individuals. Summary GnRHas remain as the only fully efficacious therapy for CPP and effectively suppress pubertal hormones in other situations. The use of GnRHa therapy in gender incongruent individuals has proven beneficial and has become a standard of care, whereas use in those with DSDs should still be considered experimental. Video abstract http://links.lww.com/MOP/A62.

show abstract

Blood Pressure Dynamics After Pubertal Suppression with Gonadotropin-Releasing Hormone Analogs Followed by Testosterone Treatment in Transgender Male Adolescents: A Pilot Study

Cited by 14 publications

References 19 publications

A systematic review of hormone treatment for children with gender dysphoria and recommendations for research

A systematic review of hormone treatment for children with gender dysphoria and recommendations for research

Gender‐affirming hormone therapy: An updated literature review with an eye on the future

Use of gonadotropin-releasing hormone analogs in children

Contact Info

Product

Resources

About